Csl Ltd has released a press release.
Half Year Results Release
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- Half Year Results Analysts Presentation
- FY2017 Profit Upgrade
- AFSTYLA (rFVIII-Single Chain) European Commission Approval
- Positive Results from CSL112 Phase 2b Trial
- Afstyla CHMP Recommendation
Later from CSL
- CSL to Acquire Majority Stake in Chinese Plasma Fractionator
- FDA approves CSL Berhings HAEGARDA
- CSL Response to Patent Infringement Complaint
- CSL Completes Acquisition of Majority Stake in Ruide
- Appendix 4E, Directors Report and Financial Statements
Follow CSL into a list and get an email when it puts out news.
Follow CSL